Oncolytic Virus Cancer Therapy Pipeline Insights Report 2018: Some of the Emerging Products include Pexa-Vec of Transgene/SillaJen, Telomelsin of Oncolys, and Canerpaturev (TBI-1401) of Takara Bio
DUBLIN, Jan. 9, 2019 /PRNewswire/ --
The "Oncolytic Virus Cancer Therapy- Pipeline Insights, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
Oncolytic Virus Cancer Therapy- Pipeline Insights, 2018 report outlays comprehensive insights of present scenario and growth prospects across Oncolytic Virus Cancer Therapy. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 65+ products with more than 25 companies involved. Some of the emerging products include Pexa-Vec of Transgene/SillaJen, Telomelsin of Oncolys, and Canerpaturev (TBI-1401) of Takara Bio.
Products covered by Phase
-- Phase III, Phase II, Phase I
-- IND
-- Pre-clinical & Discovery
-- Inactive
Overview of pipeline development activities for Oncolytic Virus Cancer Therapy
-- Pipeline analysis of therapeutic drugs include but are not limited to
drug description and development activities focusing on clinical and
pre-clinical results, designations, collaborations & licensing deals,
grants, technology and patent details.
-- Therapeutic segmentation of products for Oncolytic Virus Cancer Therapy
-- The report comprises of comparative pipeline therapeutics assessment by
development stage, therapy type, molecule type, and administration route
across this mechanism.
Key Topics Covered:
-- Executive Summary
-- Overview
-- Introduction
-- History of Oncolytic Virus
-- Mechanism of Action
Criteria of Selection on Oncolytic Virus for Cancer Therapy
-- Strategies for Tumor Targeting
-- Types of Cancer Treated
Oncolytic Viruses vs Other Therapies
-- Side effects of Oncolytic Viral Therapy
-- Limitations of Oncolytic Viral Therapy
-- Conclusion and Future Perspectives
-- Pipeline Therapeutics (Active Products)
-- Pipeline Therapeutics (Inactive Products)
-- Comparative Analysis
-- Late Stage Products (Phase III)
-- Comparative Analysis
-- Pexa-Vec: Transgene/SillaJen
-- Product Description
-- Research and Development
-- Product Development Activities
-- Mid Stage Products (Phase II)
-- Comparative Analysis
-- Telomelsin: Oncolys
-- Product Description
-- Research and Development
-- Product Development Activities
-- Early Stage Products (Phase I & IND)
-- Comparative Analysis
-- Pre-clinical and Discovery Stage Products
Comparative Analysis
-- Therapeutic Assessment: Active Products
-- Assessment by Stage and Product Type
-- Assessment by Route of Administration
-- Assessment by Stage and Route of Administration
-- Assessment by Molecule Type
-- Assessment by Stage and Molecule Type
-- Inactive Products
-- Comparative Analysis
-- Appendix
Companies Mentioned
-- SillaJen
-- Oryx
-- PsiOxus Therapeutics
-- Daiichi Sankyo
-- Vyriad
-- Genelux
-- Takara Bio
-- DNAtrix
-- Merck
-- Oncolytics Biotech
-- Oncolys BioPharma
-- Vrittu Biologics limited
-- Transgene
-- VCN Biosciences
-- CZ Biomed
-- Cell Genesys
-- Lokon Pharma
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/7zbljq/oncolytic_virus?w=5
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
